Legal Representation
Attorney
Robin Lightner Maisashvili
USPTO Deadlines
Next Deadline
2157 days remaining
Section 8 Declaration Due (Principal Register) (Based on registration date 20251111)
Due Date
November 11, 2031
Grace Period Ends
May 11, 2032
Additional deadlines exist. Contact your attorney for complete deadline information.
Application History
38 events| Date | Code | Type | Description | Documents |
|---|---|---|---|---|
| Nov 11, 2025 | NRCC | E | NOTICE OF REGISTRATION CONFIRMATION EMAILED | Loading... |
| Nov 11, 2025 | R.PR | A | REGISTERED-PRINCIPAL REGISTER | Loading... |
| Oct 21, 2025 | SUNA | E | NOTICE OF ACCEPTANCE OF STATEMENT OF USE E-MAILED | Loading... |
| Oct 21, 2025 | CNPR | P | ALLOWED PRINCIPAL REGISTER - SOU ACCEPTED | Loading... |
| Oct 2, 2025 | SUPC | I | STATEMENT OF USE PROCESSING COMPLETE | Loading... |
| May 5, 2025 | IUAF | S | USE AMENDMENT FILED | Loading... |
| Oct 2, 2025 | AITU | A | CASE ASSIGNED TO INTENT TO USE PARALEGAL | Loading... |
| May 5, 2025 | EISU | I | TEAS STATEMENT OF USE RECEIVED | Loading... |
| Mar 27, 2025 | EXRA | E | NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED | Loading... |
| Mar 27, 2025 | EX2G | S | SOU EXTENSION 2 GRANTED | Loading... |
| Mar 26, 2025 | EXT2 | S | SOU EXTENSION 2 FILED | Loading... |
| Mar 26, 2025 | EEXT | I | SOU TEAS EXTENSION RECEIVED | Loading... |
| Sep 25, 2024 | EXRA | E | NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED | Loading... |
| Sep 25, 2024 | EX1G | S | SOU EXTENSION 1 GRANTED | Loading... |
| Sep 25, 2024 | EXT1 | S | SOU EXTENSION 1 FILED | Loading... |
| Sep 25, 2024 | EEXT | I | SOU TEAS EXTENSION RECEIVED | Loading... |
| Mar 26, 2024 | NOAM | E | NOA E-MAILED - SOU REQUIRED FROM APPLICANT | Loading... |
| Jan 30, 2024 | NPUB | E | OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED | Loading... |
| Jan 30, 2024 | PUBO | A | PUBLISHED FOR OPPOSITION | Loading... |
| Jan 10, 2024 | NONP | E | NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED | Loading... |
| Dec 28, 2023 | CNSA | P | APPROVED FOR PUB - PRINCIPAL REGISTER | Loading... |
| Dec 4, 2023 | TEME | I | TEAS/EMAIL CORRESPONDENCE ENTERED | Loading... |
| Dec 4, 2023 | CRFA | I | CORRESPONDENCE RECEIVED IN LAW OFFICE | Loading... |
| Dec 4, 2023 | ALIE | A | ASSIGNED TO LIE | Loading... |
| Jun 29, 2023 | TROA | I | TEAS RESPONSE TO OFFICE ACTION RECEIVED | Loading... |
| Apr 3, 2023 | GNRN | O | NOTIFICATION OF NON-FINAL ACTION E-MAILED | Loading... |
| Apr 3, 2023 | GNRT | O | NON-FINAL ACTION E-MAILED | Loading... |
| Apr 3, 2023 | CNRT | R | NON-FINAL ACTION WRITTEN | Loading... |
| Feb 28, 2023 | TEME | I | TEAS/EMAIL CORRESPONDENCE ENTERED | Loading... |
| Feb 28, 2023 | CRFA | I | CORRESPONDENCE RECEIVED IN LAW OFFICE | Loading... |
| Feb 28, 2023 | TROA | I | TEAS RESPONSE TO OFFICE ACTION RECEIVED | Loading... |
| Aug 29, 2022 | GNRN | O | NOTIFICATION OF NON-FINAL ACTION E-MAILED | Loading... |
| Aug 29, 2022 | GNRT | F | NON-FINAL ACTION E-MAILED | Loading... |
| Aug 29, 2022 | CNRT | R | NON-FINAL ACTION WRITTEN | Loading... |
| Aug 25, 2022 | DOCK | D | ASSIGNED TO EXAMINER | Loading... |
| Apr 1, 2022 | MDSC | E | NOTICE OF DESIGN SEARCH CODE E-MAILED | Loading... |
| Mar 31, 2022 | NWOS | I | NEW APPLICATION OFFICE SUPPLIED DATA ENTERED | Loading... |
| Mar 29, 2022 | NWAP | I | NEW APPLICATION ENTERED | Loading... |
Detailed Classifications
Class 035
Promoting collaboration within the scientific, research, pharmaceutical, and medical communities to achieve advances in healthcare, including to accelerate the development and use of immunotherapy in treatment of disease
First Use Anywhere:
Nov 14, 2023
First Use in Commerce:
Nov 14, 2023
Class 036
Charitable fundraising services
First Use Anywhere:
Mar 24, 2022
First Use in Commerce:
Mar 24, 2022
Class 041
Educational services, namely, conducting programs, seminars and lectures in the fields of science and medicine relating to immunobiology, immunotherapy, wellness, cancer and diseases
First Use Anywhere:
Sep 25, 2023
First Use in Commerce:
Sep 25, 2023
Class 042
Medical research services; medical research, development, technical design, testing, and analysis services in the field of immunobiology, immunotherapy, antibodies, and oncology; consulting services in the fields of immunobiology, immunotherapy, antibodies, and oncology research, development, testing, analysis and data; medical research and development of antibodies, therapeutic products, vaccines, immunotherapy treatments and diagnostic products; medical research services in the field of immune repertoire analysis and the genome; scientific research in the fields of immunobiology, immunotherapy, antibodies and oncology; biological research; laboratory research services in the fields of immunobiology, immunotherapy, antibodies, oncology, and cellular engineering; medical laboratory services; providing information on medical and scientific research in the field of immunobiology and immunotherapy; medical and scientific research for others in the field of stem cell research, cancer, immunobiology and immunotherapy; compiling data for research purposes in the field of medical science and medical consultancy; medical and scientific research liaison services, namely, consulting in the field of scientific research pertaining to clinical trials in the fields of health care, medicine, immunobiology, immunotherapy, pharmacology and biotechnology; collection and management of medical and scientific data for research purposes in the field of medical and scientific research; pharmaceutical research services; pharmaceutical research services relating to cancer
First Use Anywhere:
Mar 24, 2022
First Use in Commerce:
Mar 24, 2022
Class 044
Medical services; Medical services relating to cancer; providing medical information; providing health information in the field of immunobiology, immunotherapy, oncology and diseases; providing a web site featuring medical information; providing a web site featuring health information in the field of immunobiology, immunotherapy, oncology and diseases; providing medical information, consultancy and advisory services; providing information on cancer treatment; providing medical information to patients and medical professionals in the field of immunotherapy and cancer treatment
First Use Anywhere:
Mar 24, 2022
First Use in Commerce:
Mar 24, 2022
Additional Information
Design Mark
The mark consists of a solid red circle with a solid dark grey square intersecting it at the upper left corner, a solid light grey square intersecting it at the upper right corner, and a dark grey square outline intersecting it at the lower right corner, and in the background, a red square outline surrounds the red circle and light grey square with the solid dark grey square and dark grey square outline extending beyond the borders of the red square outline. The color white represents background, outlining, shading, and/or transparent area and is not part of the mark.
Color Claim
The color(s) red and grey is/are claimed as a feature of the mark.
Classification
International Classes
035
036
041
042
044